1. Home
  2. MVBF vs PBYI Comparison

MVBF vs PBYI Comparison

Compare MVBF & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MVB Financial Corp.

MVBF

MVB Financial Corp.

HOLD

Current Price

$28.42

Market Cap

327.4M

Sector

Finance

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$7.33

Market Cap

343.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MVBF
PBYI
Founded
1997
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
327.4M
343.9M
IPO Year
2004
2011

Fundamental Metrics

Financial Performance
Metric
MVBF
PBYI
Price
$28.42
$7.33
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$29.50
N/A
AVG Volume (30 Days)
39.8K
175.1K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
2.63%
N/A
EPS Growth
34.64
N/A
EPS
0.39
N/A
Revenue
$3,400,000.00
$27,685,000.00
Revenue This Year
$1.70
N/A
Revenue Next Year
$13.59
N/A
P/E Ratio
$70.90
N/A
Revenue Growth
51.92
N/A
52 Week Low
$22.14
$3.03
52 Week High
$29.59
$7.90

Technical Indicators

Market Signals
Indicator
MVBF
PBYI
Relative Strength Index (RSI) 67.74 56.25
Support Level $24.66 $7.09
Resistance Level $29.13 $7.31
Average True Range (ATR) 0.71 0.25
MACD 0.19 0.02
Stochastic Oscillator 99.47 78.08

Price Performance

Historical Comparison
MVBF
PBYI

About MVBF MVB Financial Corp.

MVB Financial Corp is a financial holding company. The company provides a wide range of business activities through the Bank, commercial and retail banking services, as well as Fintech banking. It has three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of its revenue is generated from the CoRe Banking segment, which includes its Fintech division, represents banking products and services offered to customers by the Bank, loans and deposits accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: